Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632670 | 0.82 | HDAC1 (0.56) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL13706438 | 0.81 | HDAC1 (0.55) | GSK3BHDAC1HDAC6KDM4EKMT2A | |
| SCHEMBL14683904 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL15136337 | 0.81 | HDAC1 (0.55) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL15920457 | 0.81 | HDAC1 (0.55) | GSK3BHDAC1HDAC6KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL3231047 | 0.79 | HDAC1 (0.53) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL10812902 | 0.79 | HDAC1 (0.58) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL9672401 | 0.79 | HDAC1 (0.53) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL27386679 | 0.79 | HSD17B3 (0.53) | HDAC1HDAC6KDM4EKMT2AMAPT | |
| SCHEMBL16601153 | 0.78 | PTPN1 (0.55) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-29 | — | — | US | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-4031531-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120323002-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-2518072-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| WO-2011126960-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-2227466-B1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885HDAC1 871/4885HDAC6 2355/4885 |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885HDAC1 713/4885HDAC6 1338/4885 |
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, ALOX5 | GSK3B 973/4885HDAC1 804/4885HDAC6 833/4885 |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | GSK3B 4125/4885HDAC1 736/4885HDAC6 927/4885 |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | GSK3B 4498/4885HDAC1 1895/4885HDAC6 3615/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885HDAC1 713/4885HDAC6 1338/4885 |
| US-20120323002-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | IL23R, IL15, IL5 | GSK3B 639/4885HDAC1 106/4885HDAC6 77/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | GSK3B 3281/4885HDAC1 871/4885HDAC6 2355/4885 |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885HDAC1 713/4885HDAC6 1338/4885 |
| US-20220411388-A1 | SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, CLN6 | GSK3B 3304/4885HDAC1 107/4885HDAC6 12/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3153/4885HDAC1 678/4885HDAC6 1010/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | GSK3B 4125/4885HDAC1 736/4885HDAC6 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.